

The supply of plasma-derived medicinal products in the future of Europe

Second edition

23-24
April 2024
Rome, Italy

CENTRO
NAZIONALE
SANGUE

 PLASMA
ITALIA
italiaplasma.it

with the patronage of



Ministero della Salute

Plasma derived products demand A Canadian perspective

Sylvain Grenier, B Pharm, PharmD, FFIP, FOPQ

Director, PPRP Formulary Program

Canadian Blood Services, Canada

Disclosure

- No conflict of interest to disclose




Outline

- Canadian Blood Services Overview
- Trends post-pandemic
- Plasma Derived Products
 - Immunoglobulins
 - Albumin
 - rFVIII/emicizumab
 - C1-esterase inhibitors
 - Fibrinogen concentrate
- Plasma Sufficiency




Our locations



Introductory Overview: Plasma Protein and Related Products (PPRP) formulary

- Plasma Protein and Related Products (synthetic alternatives)
- Bulk purchase about 50 brands worth ~ \$950M annually
- Mainly public tendering process
- Equity of access for patients across the country



Trends post-pandemic

- Overall demand is back to pre-pandemic growth and a bit more in some areas
- Initial hospital use decreased due to deprioritizing of surgeries and other treatments, now we see a catching up effect
- Home use saw a significant increase in demand early in the pandemic (March 2020) followed by an initial decrease and then stabilization




Immunoglobulins

Immunoglobulin 5 year trend by population

Total grams per 1,000 population


* FY2023/24 Forecast is based on Dec 31 year-to-date actuals



Immunoglobulin provincial comparison by population - FY2023/24 vs. FY2022/23

Total grams per 1,000 population


* FY2023/24 Forecast is based on Dec 31 year-to-date actuals



Albumin

Albumin 5 year trend by population
Total 25 gm units per 1,000 population

* FY2023/24 Forecast is based on Dec 31 year-to-date actuals




rFVIII (SHL-EHL combined)

Recombinant Factor VIII 5 year trend by population

* FY2023/24 Forecast is based on Dec 31 year-to-date actuals

Total IU per 1,000 population



	FY2019/20	FY2020/21	FY2021/22	FY2022/23	FY2023/24
■	-	-	-	-	-
■ Recombinant Factor VIII	8,198.03	7,083.43	6,942.41	4,572.12	3,724.88
■ Growth %	12.6%	-12.2%	-1.6%	-33.2%	-16.1%




Emicizumab (Hemlibra[®])

Hemlibra. 5 year trend by population

Total milligrams per 1,000 population

* FY2023/24 Forecast is based on Dec 31 year-to-date actuals



HA: Hemophilia A




C1-esterase inhibitors

C1-inhibitor year trend by population

* FY2023/24 Forecast is based on Dec 31 year-to-date actuals

Total IU per 1,000 population




Fibrinogen concentrate

Fibrinogen 5 year trend by population

Total grams per 1,000 population

* FY2023/24 Forecast is based on Dec 31 year-to-date actuals



Ensure a secure supply of Canadian plasma for immunoglobulin



What will this look like in action?

- Increase Canada's domestic immunoglobulin sufficiency
- Significantly increase capacity for source plasma collection within a national network
- Diversify sources of supply to respond to major supply disruptions



Plasma donor centre strategy execution

Operating



Sudbury
Aug
2020



Lethbridge
Dec
2020



Kelowna
Jun
2021



Brampton
May
2022



Ottawa
May
2022



Abbotsford
April
2023



Vaughan
May
2023



St. Catharines
June
2023



Windsor
January
2024

Planning



TBD
2024



TBD
2024

- The source plasma sufficiency rate for Immunoglobulin **is currently at 19%**
- When factoring in Grifols collected plasma to Canadian sufficiency, the rate is **27%**



Questions?



